论文部分内容阅读
目的探讨三磷酸腺苷(ATP)生物荧光法(ATP-TCA体外药敏试验)对肺癌一线治疗失败后二线治疗预测疗效的可行性。方法应用ATP-TCA体外药敏试验对42例肺癌患者组织或细胞标本进行体外药敏检测。结果 42例肺癌标本的可评估率95.2%,其中鳞癌对吉西他滨联合顺铂体外敏感率最高(47.6%),而对培美曲塞二钠联合顺铂的敏感率最低(22.7%),两者差异有统计学意义(P<0.05)。对多西他赛、紫杉醇、长春瑞滨、伊立替康联合顺铂的敏感率介于中间;对于腺癌,培美曲塞二钠联合顺铂的有效率最高(50.0%),吉西他滨联合顺铂的有效率最低(23.8%)(P<0.05);对于小细胞肺癌,伊立替康联合顺铂的有效率最高(50.0%),而吉西他滨、多西他赛、培美曲塞二钠、长春瑞滨、紫杉醇联合顺铂的有效例数稍有减低,但差异无统计学意义。结论肺癌对抗癌药物的敏感性存在异质性,采用ATP-TCA可有效预测临床化疗敏感性,指导肺癌的个体化治疗。
Objective To investigate the feasibility of second-line treatment of lung cancer after failed first-line treatment with adenosine triphosphate (ATP) biofluorescence assay (ATP-TCA in vitro susceptibility test). Methods ATP-TCA in vitro susceptibility testing of 42 cases of lung cancer tissue samples or cells in vitro susceptibility testing. Results The evaluable rate of lung cancer specimens was 95.2%. The sensitivity rate of squamous cell carcinoma to gemcitabine combined with cisplatin was the highest (47.6%) and the lowest (22.7%) to pemetrexed disodium combined with cisplatin The difference was statistically significant (P <0.05). For docetaxel, paclitaxel, vinorelbine, irinotecan combined with cisplatin in the middle; for adenocarcinoma, pemetrexed disodium combined with cisplatin the highest efficiency (50.0%), gemcitabine combined cis The efficiency of platinum was the lowest (23.8%) (P <0.05); for small cell lung cancer, irinotecan combined with cisplatin was the most effective (50.0%), while gemcitabine, docetaxel, pemetrexed disodium, Vinorelbine, paclitaxel combined with cisplatin effective number slightly reduced, but the difference was not statistically significant. Conclusion The sensitivity of lung cancer to anticancer drugs is heterogeneous. ATP-TCA can effectively predict the sensitivity of chemotherapy and guide the individualized treatment of lung cancer.